Overview

* Chemours Q2 2025 net sales rise 4%, beating analyst expectations, per LSEG data

* Adjusted EPS for Q2 2025 beats consensus at $0.58, per LSEG data

* Co reports net loss due to litigation charges, adjusted EBITDA beats estimates

Outlook

* Chemours ( CC ) expects Q3 net sales to decrease 4-6% sequentially

* Company anticipates Q3 adjusted EBITDA between $175 mln and $195 mln

* Chemours ( CC ) forecasts full-year net sales of $5.9 bln to $6.0 bln

* Company sees full-year adjusted EBITDA of $775 mln to $825 mln

Result Drivers

* OPTEON™ REFRIGERANTS - Strong demand for Opteon™ Refrigerants drove sales growth in Thermal & Specialized Solutions

* PRICING STRATEGY - Favorable pricing in Advanced Performance Materials contributed to sales increase

* LITIGATION CHARGES - Net loss primarily due to litigation-related charges from settlement with New Jersey

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $1.60 $1.56

bln bln (6

Analysts

)

Q2 Beat $0.58 $0.46 (9

Adjusted Analysts

EPS )

Q2 Beat $253 mln $224 mln

Adjusted (6

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the diversified chemicals peer group is "buy."

* Wall Street's median 12-month price target for Chemours Co ( CC ) is $15.00, about 15.8% above its August 5 closing price of $12.63

* The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 6 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)